Comparison of Intravitreal Bevacizumab to Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: Short-term Results

Overview

Journal Indian J Ophthalmol

Specialty Ophthalmology

Date 2010 Jun 11

PMID 20534918

Citations 7

Authors

Yoshinori Mitamura

Masayasu Kitahashi

Mariko Kubota-Taniai

Shuichi Yamamoto

Affiliations

Soon will be listed here.

Abstract

Aims: To compare the short-term therapeutic effects of intravitreal bevacizumab (IVB) to those of photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV).

Materials And Methods: Retrospective interventional case study. Eighty-nine eyes of 89 patients with symptomatic PCV were treated by IVB or PDT. Eighteen eyes were treated with a single injection of IVB (s-IVB group), 22 eyes with three consecutive monthly IVB injections (m-IVB group), and 49 eyes with PDT alone (PDT group). The best-corrected visual acuity (BCVA) and OCT-determined central foveal thickness (CFT) were evaluated before, and one and three months after the treatment. For statistical analyses, one-factor ANOVA and Chi-square test were used.

Results: The differences in the BCVA and CFT among the three groups at the baseline were not significant (P=0.992, P=0.981, respectively). Three months after the treatment, the BCVA improved by> 0.2 logMAR units in two out of 18 eyes (11%) in the s-IVB group, three out of 22 eyes (14%) in the m-IVB group, and 15 out of 49 eyes (31%) in the PDT group (P=0.124). A decrease in the CFT by> 20% was achieved in six out of 18 eyes in the s-IVB group, ten eyes (46%) in the m-IVB group, and 35 eyes (71%) in the PDT group (P=0.009). The resolution of polyps was achieved in three out of 18 eyes in the s-IVB group, one eye (5%) in the m-IVB group and 35 eyes (71%) in the PDT group (P < 0.001).

Conclusion: The better short-term therapeutic outcomes in the PDT group than in the s-IVB and m-IVB groups indicate that PDT may be more effective than IVB in short term after treatment for PCV.

Citing Articles

Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.

Lai K, Li Y, Zhou L, Zhong X, Huang C, Xu F BMC Ophthalmol. 2018; 18(1):144.

PMID: 29925341 PMC: 6011514. DOI: 10.1186/s12886-018-0801-7.

Polypoidal choroidal vasculopathy treatment options: A meta-analysis.

Qian T, Li X, Zhao M, Xu X Eur J Clin Invest. 2017; 48(1).

PMID: 28981139 PMC: 5771464. DOI: 10.1111/eci.12840.

Polypoidal Choroidal Vasculopathy in Asians.

Wong C, Wong T, Cheung C J Clin Med. 2015; 4(5):782-821.

PMID: 26239448 PMC: 4470199. DOI: 10.3390/jcm4050782.

Photodynamic therapy versus anti-vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: a meta-analysis.

Yong M, Zhou M, Deng G BMC Ophthalmol. 2015; 15:82.

PMID: 26209516 PMC: 4513969. DOI: 10.1186/s12886-015-0064-5.

Spectral-domain optical coherence tomography findings in polypoidal choroidal vasculopathy suggest a type 1 neovascular growth pattern.

Alshahrani S, Al Shamsi H, Kahtani E, Ghazi N Clin Ophthalmol. 2014; 8:1689-95.

PMID: 25214762 PMC: 4159396. DOI: 10.2147/OPTH.S68471.

References

Lai T, Chan W, Liu D, Luk F, Lam D . Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008; 92(5):661-6. DOI: 10.1136/bjo.2007.135103. View

Sayanagi K, Gomi F, Sawa M, Ohji M, Tano Y . Long-term follow-up of polypoidal choroidal vasculopathy after photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol. 2007; 245(10):1569-71. DOI: 10.1007/s00417-007-0582-9. View

Tatar O, Adam A, Shinoda K, Stalmans P, Eckardt C, Luke M . Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol. 2006; 142(1):95-104. DOI: 10.1016/j.ajo.2006.01.085. View

Song J, Byeon S, Lee S, Koh H, Kwon O . Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy. Ophthalmologica. 2008; 223(2):85-92. DOI: 10.1159/000175312. View

Pedersen K, Sjolie A, Moller F . Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients. Acta Ophthalmol. 2008; 87(7):714-9. DOI: 10.1111/j.1755-3768.2008.01346.x. View

Pai S, Shetty R . Sequential therapy with intravitreal bevacizumab and photodynamic therapy for idiopathic polypoidal choroidal vasculopathy. Acta Ophthalmol. 2008; 87(7):806-7. DOI: 10.1111/j.1755-3768.2008.01330.x. View

Tong J, Chan W, Liu D, Lai T, Choy K, Pang C . Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006; 141(3):456-62. DOI: 10.1016/j.ajo.2005.10.012. View

. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic.... Arch Ophthalmol. 1999; 117(10):1329-45. View

Rosenfeld P, Moshfeghi A, Puliafito C . Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005; 36(4):331-5. View

10.

Mitamura Y, Kubota-Taniai M, Okada K, Kitahashi M, Baba T, Mizunoya S . Comparison of photodynamic therapy to transpupillary thermotherapy for polypoidal choroidal vasculopathy. Eye (Lond). 2007; 23(1):67-72. DOI: 10.1038/sj.eye.6702996. View

11.

Spaide R, Laud K, Fine H, Klancnik Jr J, Meyerle C, Yannuzzi L . Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006; 26(4):383-90. DOI: 10.1097/01.iae.0000238561.99283.0e. View

12.

Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y . One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology. 2007; 115(1):141-6. DOI: 10.1016/j.ophtha.2007.02.031. View

13.

Bashshur Z, Bazarbachi A, Schakal A, Haddad Z, El Haibi C, Noureddin B . Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006; 142(1):1-9. DOI: 10.1016/j.ajo.2006.02.037. View

14.

Maruko I, Iida T, Saito M, Nagayama D, Saito K . Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007; 144(1):15-22. DOI: 10.1016/j.ajo.2007.03.047. View

15.

Silva R, Figueira J, Luz Cachulo M, Duarte L, de Abreu J, Cunha-Vaz J . Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol. 2005; 243(10):973-9. DOI: 10.1007/s00417-005-1139-4. View

16.

Yannuzzi L, Sorenson J, Spaide R, Lipson B . Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990; 10(1):1-8. View

17.

Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M . Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2007; 92(1):70-3. DOI: 10.1136/bjo.2007.122283. View

18.

Spaide R, Donsoff I, Lam D, Yannuzzi L, Jampol L, Slakter J . Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina. 2002; 22(5):529-35. DOI: 10.1097/00006982-200210000-00001. View

19.

Shahar J, Avery R, Heilweil G, Barak A, Zemel E, Lewis G . Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006; 26(3):262-9. DOI: 10.1097/00006982-200603000-00002. View

20.

Lee S, Kim J, Joe S, Chung H, Yoon Y . The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy. Korean J Ophthalmol. 2008; 22(2):92-9. PMC: 2629943. DOI: 10.3341/kjo.2008.22.2.92. View